Literature DB >> 9463314

ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer.

T Stankovic1, A M Kidd, A Sutcliffe, G M McGuire, P Robinson, P Weber, T Bedenham, A R Bradwell, D F Easton, G G Lennox, N Haites, P J Byrd, A M Taylor.   

Abstract

We report the spectrum of 59 ATM mutations observed in ataxia-telangiectasia (A-T) patients in the British Isles. Of 51 ATM mutations identified in families native to the British Isles, 11 were founder mutations, and 2 of these 11 conferred a milder clinical phenotype with respect to both cerebellar degeneration and cellular features. We report, in two A-T families, an ATM mutation (7271T-->G) that may be associated with an increased risk of breast cancer in both homozygotes and heterozygotes (relative risk 12.7; P=. 0025), although there is a less severe A-T phenotype in terms of the degree of cerebellar degeneration. This mutation (7271T-->G) also allows expression of full-length ATM protein at a level comparable with that in unaffected individuals. In addition, we have studied 18 A-T patients, in 15 families, who developed leukemia, lymphoma, preleukemic T-cell proliferation, or Hodgkin lymphoma, mostly in childhood. A wide variety of ATM mutation types, including missense mutations and in-frame deletions, were seen in these patients. We also show that 25% of all A-T patients carried in-frame deletions or missense mutations, many of which were also associated with expression of mutant ATM protein.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9463314      PMCID: PMC1376883          DOI: 10.1086/301706

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  23 in total

1.  Ataxia-telangiectasia: mutations in ATM cDNA detected by protein-truncation screening.

Authors:  M Telatar; Z Wang; N Udar; T Liang; E Bernatowska-Matuszkiewicz; M Lavin; Y Shiloh; P Concannon; R A Good; R A Gatti
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

2.  Restriction endonuclease fingerprinting (REF): a sensitive method for screening mutations in long, contiguous segments of DNA.

Authors:  Q Liu; S S Sommer
Journal:  Biotechniques       Date:  1995-03       Impact factor: 1.993

3.  The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species.

Authors:  K Savitsky; S Sfez; D A Tagle; Y Ziv; A Sartiel; F S Collins; Y Shiloh; G Rotman
Journal:  Hum Mol Genet       Date:  1995-11       Impact factor: 6.150

4.  The incidence and gene frequency of ataxia-telangiectasia in the United States.

Authors:  M Swift; D Morrell; E Cromartie; A R Chamberlin; M H Skolnick; D T Bishop
Journal:  Am J Hum Genet       Date:  1986-11       Impact factor: 11.025

5.  Cytogenetic anomalies in a patient with ataxia, immune deficiency, and high alpha-fetoprotein in the absence of telangiectasia.

Authors:  K L Ying; W E Decoteau
Journal:  Cancer Genet Cytogenet       Date:  1981-12

Review 6.  Leukemia and lymphoma in ataxia telangiectasia.

Authors:  A M Taylor; J A Metcalfe; J Thick; Y F Mak
Journal:  Blood       Date:  1996-01-15       Impact factor: 22.113

Review 7.  Cancer risks in A-T heterozygotes.

Authors:  D F Easton
Journal:  Int J Radiat Biol       Date:  1994-12       Impact factor: 2.694

8.  A single ataxia telangiectasia gene with a product similar to PI-3 kinase.

Authors:  K Savitsky; A Bar-Shira; S Gilad; G Rotman; Y Ziv; L Vanagaite; D A Tagle; S Smith; T Uziel; S Sfez; M Ashkenazi; I Pecker; M Frydman; R Harnik; S R Patanjali; A Simmons; G A Clines; A Sartiel; R A Gatti; L Chessa; O Sanal; M F Lavin; N G Jaspers; A M Taylor; C F Arlett; T Miki; S M Weissman; M Lovett; F S Collins; Y Shiloh
Journal:  Science       Date:  1995-06-23       Impact factor: 47.728

9.  Incidence of cancer in 161 families affected by ataxia-telangiectasia.

Authors:  M Swift; D Morrell; R B Massey; C L Chase
Journal:  N Engl J Med       Date:  1991-12-26       Impact factor: 91.245

10.  Predominance of null mutations in ataxia-telangiectasia.

Authors:  S Gilad; R Khosravi; D Shkedy; T Uziel; Y Ziv; K Savitsky; G Rotman; S Smith; L Chessa; T J Jorgensen; R Harnik; M Frydman; O Sanal; S Portnoi; Z Goldwicz; N G Jaspers; R A Gatti; G Lenoir; M F Lavin; K Tatsumi; R D Wegner; Y Shiloh; A Bar-Shira
Journal:  Hum Mol Genet       Date:  1996-04       Impact factor: 6.150

View more
  87 in total

Review 1.  The pathogenesis of ataxia-telangiectasia. Learning from a Rosetta Stone.

Authors:  R A Gatti; S Becker-Catania; H H Chun; X Sun; M Mitui; C H Lai; N Khanlou; M Babaei; R Cheng; C Clark; Y Huo; N C Udar; R K Iyer
Journal:  Clin Rev Allergy Immunol       Date:  2001-02       Impact factor: 8.667

2.  Haplotypes at ATM identify coding-sequence variation and indicate a region of extensive linkage disequilibrium.

Authors:  P E Bonnen; M D Story; C L Ashorn; T A Buchholz; M M Weil; D L Nelson
Journal:  Am J Hum Genet       Date:  2000-11-14       Impact factor: 11.025

Review 3.  Immunodeficiency associated with DNA repair defects.

Authors:  A R Gennery; A J Cant; P A Jeggo
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

Review 4.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

5.  Underexpression and abnormal localization of ATM products in ataxia telangiectasia patients bearing ATM missense mutations.

Authors:  Virginie Jacquemin; Guillaume Rieunier; Sandrine Jacob; Dorine Bellanger; Catherine Dubois d'Enghien; Anthony Laugé; Dominique Stoppa-Lyonnet; Marc-Henri Stern
Journal:  Eur J Hum Genet       Date:  2011-11-09       Impact factor: 4.246

6.  Characterisation of ATM mutations in Slavic Ataxia telangiectasia patients.

Authors:  Jana Soukupova; Petr Pohlreich; Eva Seemanova
Journal:  Neuromolecular Med       Date:  2011-08-11       Impact factor: 3.843

7.  Mantle cell lymphoma is characterized by inactivation of the ATM gene.

Authors:  C Schaffner; I Idler; S Stilgenbauer; H Döhner; P Lichter
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

8.  Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer.

Authors:  Shaun P Scott; Regina Bendix; Philip Chen; Raymond Clark; Thilo Dork; Martin F Lavin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

9.  The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer.

Authors:  Denise L Stredrick; Montserrat Garcia-Closas; Marbin A Pineda; Parveen Bhatti; Bruce H Alexander; Michele M Doody; Jolanta Lissowska; Beata Peplonska; Louise A Brinton; Stephen J Chanock; Jeffery P Struewing; Alice J Sigurdson
Journal:  Hum Mutat       Date:  2006-06       Impact factor: 4.878

10.  ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.

Authors:  Veronika Navrkalova; Ludmila Sebejova; Jana Zemanova; Jana Kminkova; Blanka Kubesova; Jitka Malcikova; Marek Mraz; Jana Smardova; Sarka Pavlova; Michael Doubek; Yvona Brychtova; David Potesil; Veronika Nemethova; Jiri Mayer; Sarka Pospisilova; Martin Trbusek
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.